Journal article
New developments and directions in the clinical application of the echinocandins
CC Chang, MA Slavin, SCA Chen
Archives of Toxicology | SPRINGER HEIDELBERG | Published : 2017
Abstract
The echinocandins—caspofungin, anidulafungin and micafungin—are semi-synthetic cyclic hexapeptide antimicrobial agents with modified N-linked acyl lipid side chains which anchor the compounds to the phospholipid bilayer of the fungal cell membrane, thereby inhibiting synthesis of fungal cell wall glucan. Over the last 10 years, echinocandins have become the first-line antifungal treatment of candidaemia and other forms of invasive candidiasis (IC). Echinocandins are generally well tolerated, but their use is limited by their requirement for daily intravenous dosing, lack of oral formulation and limited spectrum. In critically ill patients, it is also recognised that achievement of their phar..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
All authors declared that there is no conflict of interest. SC-AC and MAS are members of the Antifungal Advisory Boards of Gilead Sciences Inc., Merck, and Pfizer, Australia, and have received untied investigator-initiated grants from Pfizer Australia, Gilead Sciences and Merck.